A Randomized, Open-label, Single Oral Dose, Three-arm, Parallel Design, Phase 1 Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Volunteers
Latest Information Update: 02 Apr 2025
At a glance
- Drugs BR 1400 (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 02 Apr 2025 New trial record